1. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis
- Author
-
Syu-ichi Higashi, Michishi Tsukano, Kunihiko Tomoda, Tadashi Nakamura, and Masahiro Shono
- Subjects
Male ,medicine.medical_specialty ,Genotype ,Renal function ,Gastroenterology ,Receptors, Tumor Necrosis Factor ,Etanercept ,Arthritis, Rheumatoid ,chemistry.chemical_compound ,Japan ,Rheumatology ,AA amyloidosis ,Internal medicine ,medicine ,Humans ,Renal Insufficiency ,Serum amyloid A ,Serum Amyloid A Protein ,Aged ,Creatinine ,Proteinuria ,business.industry ,Amyloidosis ,Anti-Inflammatory Agents, Non-Steroidal ,General Medicine ,Middle Aged ,medicine.disease ,stomatognathic diseases ,Endocrinology ,chemistry ,Immunoglobulin G ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
The benefit of biological therapies in rheumatoid arthritis (RA) treatment is well known, but their role in amyloid A (AA) amyloidosis secondary to RA is unclear. The aim of this study was to clarify the clinical benefit of etanercept in RA patients with AA amyloidosis. We treated 14 RA patients who had serum amyloid A protein (SAA) 1.3 allele, with biopsy-confirmed AA amyloidosis with etanercept and investigated the efficacy of etanercept treatment, focusing on renal function retrospectively. The AA amyloidosis improved and stabilized after 89.1 ± 27.2 weeks. Proteinuria decreased from 2.24 ± 0.81 to 0.57 ± 0.41 g/day (P < 0.01) and SAA fell from 250 ± 129 to 26 ± 15μg/ml (P < 0.01), respectively. Diarrhea secondary to gastrointestinal AA amyloidosis was less. Overall, the serum creatinine levels did not benefit with treatment, but in those with a creatinine values more...
- Published
- 2010
- Full Text
- View/download PDF